**Overview**

Desoxyn® (methamphetamine) is a member of the amphetamine group of sympathomimetic amines indicated for Attention Deficit Hyperactivity Disorder (ADHD) as an integral part of a total treatment program and Exogenous Obesity as a short term adjust in a regimen of weight reduction based on caloric restriction for patients in whom obesity is refractory to alternative therapy (e.g., repeated diets, group programs, other drugs).

**Coverage Guidelines**

Authorization may be granted when the following criteria are met:

1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) **AND**
2. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to a trial (defined as ≥ 7 days of therapy) to ALL other stimulant and non-stimulant options

*Note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.*

**Continuation of Therapy**

Reauthorization requires physician documentation indicating a positive response to therapy.

**Limitations**

1. Approvals will be granted for 12 months

**Appendix**

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org

AllWays Health Partners includes AllWays Health Partners, Inc. and AllWays Health Partners Insurance Company
Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of both a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

References
1. Desoxyn (methamphetamine) [package insert]. Lebanon (NJ): Recordati Rare Diseases Inc; 2019 March

Review History
03/01/18 – Effective (adopted MH RS)
04/17/19 – Reviewed in P&T Meeting

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.